Simoa is considerably advancing the study of concussions because researchers are using it to detect biomarkers — proteins whose concentrations can be indicative of TBI — that were previously undetectable. The most well-known of these concussion biomarkers is a protein called tau.
In The News
SportTechie| May 17, 2017
Clinical Lab Products | May 2017
Our ultra-sensitive Simoa platform and complete assay kits were featured in this month’s issue of Clinical Lab Products magazine. View our listing on page 26
May 5, 2017 | Cheddar
Cheddar, the live and on demand video news network focused on covering the most innovative products, technologies and services transforming our lives, recently interviewed Quanterix CEO and Executive Chairman Kevin Hrusovsky.
May 2, 2017 | Boston, MA
View the recording of the panel discussion “Precision Cardiovascular Medicine: What is Different This Time” which took place at the World Medical Innovation Forum on May 2, 2017
Alzforum | April 20, 2017
Tau pathology is linked with neurodegeneration in multiple tauopathies, and efforts are underway to vanquish this tangle-forming protein with anti-tau antibodies.
MedPage Today | March 28, 2017
Neurofilament light levels correlated with mental deficits but short on specificity
The Washington Post | March 27, 2017
The NFL is in search of what Jeff Miller, the league's senior vice president of health and safety policy, described as a more “objective” test for traumatic brain injury (TBI).
Boston Vision | March 2017
An interview with Director of software engineering and informatics Tomasz Piech, who manages the development of software systems required to run our Simoa operations.
Undark | March 14, 2017
A new ecosystem of portable technologies has the potential to enhance our ability to treat and mitigate the effects of head trauma.